ANTICORPS THÉRAPEUTIQUES

• 收藏
• 分享

专利权人:

Novo Nordisk A/S

发明人:

申请号：

EP12725447.2

公开号：

EP2718322B1

申请日:

2012.06.04

申请国别(地区):

EP

年份:

2018

代理人:

摘要：

The present invention concerns human antibodies recognizing the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signaling, whereby the pro- inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/